Epizyme (NASDAQ:EPZM) has been assigned a $26.00 price target by equities research analysts at Oppenheimer in a report issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s target price points to a potential upside of 96.23% from the company’s current price.

A number of other brokerages have also issued reports on EPZM. Royal Bank of Canada lowered shares of Epizyme from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $20.00 to $16.00 in a research note on Thursday, November 2nd. Cann reiterated a “buy” rating and set a $26.00 price target on shares of Epizyme in a research note on Thursday, November 2nd. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Epizyme in a research note on Thursday, November 2nd. ValuEngine lowered shares of Epizyme from a “hold” rating to a “sell” rating in a research note on Monday, November 6th. Finally, Leerink Swann reiterated an “outperform” rating and set a $22.00 price target (down from $28.00) on shares of Epizyme in a research note on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $22.67.

Shares of Epizyme (NASDAQ EPZM) opened at $13.25 on Tuesday. Epizyme has a 1-year low of $9.30 and a 1-year high of $20.45.

Epizyme (NASDAQ:EPZM) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02. research analysts expect that Epizyme will post -2.23 earnings per share for the current fiscal year.

In related news, Director David M. Mott bought 200,000 shares of the stock in a transaction on Monday, September 18th. The shares were bought at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the transaction, the director now owns 6,000 shares of the company’s stock, valued at approximately $91,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total transaction of $246,600.00. Following the transaction, the insider now owns 23,123 shares in the company, valued at $380,142.12. The disclosure for this sale can be found here. Corporate insiders own 25.20% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. acquired a new position in Epizyme during the third quarter worth about $17,591,000. University of Notre Dame DU Lac grew its position in Epizyme by 25.0% during the third quarter. University of Notre Dame DU Lac now owns 191,719 shares of the biopharmaceutical company’s stock worth $3,652,000 after buying an additional 38,368 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of Epizyme by 42.5% in the third quarter. Schwab Charles Investment Management Inc. now owns 217,168 shares of the biopharmaceutical company’s stock valued at $4,138,000 after purchasing an additional 64,721 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Epizyme by 17.3% in the third quarter. Wells Fargo & Company MN now owns 36,473 shares of the biopharmaceutical company’s stock valued at $695,000 after purchasing an additional 5,376 shares during the last quarter. Finally, Trexquant Investment LP grew its position in shares of Epizyme by 134.3% in the third quarter. Trexquant Investment LP now owns 28,593 shares of the biopharmaceutical company’s stock valued at $545,000 after purchasing an additional 16,387 shares during the last quarter. Institutional investors own 85.28% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/12/14/epizyme-epzm-given-a-26-00-price-target-by-oppenheimer-analysts.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.